- Home
- NRXP vs VRCA Comparison
NRXP vs VRCA Comparison
Compare NRXP & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NRXP | VRCA |
|---|---|---|
| Founded | 2015 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.7M | 32.7M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | NRXP | VRCA |
|---|---|---|
| Price | $2.36 | $8.90 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 2 |
| Target Price | ★ $30.50 | N/A |
| AVG Volume (30 Days) | ★ 446.3K | 378.4K |
| Earning Date | 11-17-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $242,000.00 | ★ $30,829,000.00 |
| Revenue This Year | N/A | $373.65 |
| Revenue Next Year | $643.59 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 234.73 |
| 52 Week Low | $1.15 | $3.28 |
| 52 Week High | $6.01 | $12.00 |
Technical Indicators
Market Signals| Indicator | NRXP | VRCA |
|---|---|---|
| Relative Strength Index (RSI) | 45.23 | 71.77 |
| Support Level | $2.22 | $6.26 |
| Resistance Level | $2.51 | $9.82 |
| Average True Range (ATR) | 0.19 | 1.02 |
| MACD | 0.04 | 0.42 |
| Stochastic Oscillator | 68.52 | 83.64 |
Price Performance
Historical ComparisonAbout NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.